Emily Menendez

GU Oncology Now

Clinical trials that investigate treatment effectiveness in patients affected by high-risk non-muscle-invasive bladder cancer (HR-NMIBC) often use progression-free survival (PFS) as a surrogate end point. However, the efficacy of this surrogate end point and its association with overall survival (OS) are challenged by conflicting results that demonstrate lack of OS advantage, even when in the presence of PFS improvement.<a href="https://www.auajournals.org/doi/10.1097/JU.0000000000003223.03" target="_blank" rel="noopener">A new study presented</a> at the American Urological Association 2023 Annual Meeting sought to test the effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical bacillus Calmette-Gu&eacute;rin therapy.A total of 1510 patients at first diagnosis of T1 HR-NMIBC after transurethral resection of bladder tumor were included in the study. Procedures were performed across 18 different tertiary institutions between 2002 and 2012. Progression was defined as the time from HR-NMIBC diagnosis to development of muscle-invasive bladder cancer (MIBC). Covariates were ranked based on OS prediction, and classes were obtained based on time to progression. Cox regression models were then utilized.At a median follow-up of 49 months, 483 patients had disease progression to MIBC, while 163 patients died. The median time to progression was 82 months. In relapse-free survival, time to progression and age were the most predictive components of OS. The C-index was 0.814 on the training set and 0.726 on the test set. The survival tree including these covariates defined 5 risk groups:<ul>
<li>PFS &ge;62.5 months and age &lt;77.5 years (reference)</li>
<li>PFS &ge;62.5 months and age &ge;77.5 years (hazard ratio [HR], 9.0; P&lt;.001)</li>
<li>PFS between 10.5 and 62.5 months and age &lt;79.5 years (HR, 14.3; P&lt;.001)</li>
<li>PFS &lt;10.5 months and age &lt;79.5 (HR, 44.9; P&lt;.001)</li>
<li>PFS &lt;62.5 months and age &ge;79.5 years (HR, 58.7; P&lt;.001).</li>
</ul>In multivariable Cox regression models accounting for progression status as a time-dependent covariate, longer PFS (as a continuous covariate) was associated with a longer OS (HR, 0.9; P&lt;.001). Results were virtually the same after PFS stratification (PFS &ge;10.5 months as reference) and included PFS between 10.5 and 62.5 months (HR, 0.4; P&lt;.001) and PFS &ge;62.5 months (HR, 0.2; P&lt;.001).PFS can be utilized as an efficient surrogate end point for OS due to its strong predictor status and high accuracy. Further studies evaluating the efficacy of HR-NMIBC treatments can benefit from using PFS as a surrogate for OS.

PFS Is an Effective OS Surrogate for NMIBC

AUA 2023: Focus on Bladder Cancer

A study presented at AUA 2023 sought to test the effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical BCG.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe